Head-To-Head Review: Zicix (OTCMKTS:ZICX) & Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ:VCYT) and Zicix (OTCMKTS:ZICX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Risk and Volatility

Veracyte has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Zicix has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Veracyte and Zicix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	-2.18%	3.02%	2.80%
Zicix	N/A	N/A	N/A

Valuation & Earnings

This table compares Veracyte and Zicix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$361.05 million	8.29	-$74.40 million	($0.15)	-257.33
Zicix	N/A	N/A	N/A	N/A	N/A

Zicix has lower revenue, but higher earnings than Veracyte.

Analyst Recommendations

This is a summary of current recommendations for Veracyte and Zicix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	0	8	0	2.78
Zicix	0	0	0	0	0.00

Veracyte presently has a consensus price target of $41.25, indicating a potential upside of 6.87%. Given Veracyte’s stronger consensus rating and higher possible upside, research analysts clearly believe Veracyte is more favorable than Zicix.

Summary

Veracyte beats Zicix on 7 of the 8 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.